Seelos Therapeutics, Inc. (SEEL)
USD 0.37
(-31.49%)
USD 0.37
(-31.49%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.91 Million | -61.6 Million | -48.99 Million | -20.91 Million | -19.3 Million | -8.12 Million |
| Net Income | -37.88 Million | -73.53 Million | -66.04 Million | -19.1 Million | -51.25 Million | -9.21 Million |
| Depreciation & Amortization | 57 Thousand | 53 Thousand | 1.58 Million | 150 Thousand | - | 41 Thousand |
| Deferred income taxes | 7.91 Million | - | -1.58 Million | -150 Thousand | - | -24 Thousand |
| Stock-based compensation | 3.98 Million | 5.07 Million | 8.34 Million | 2.04 Million | 459 Thousand | 1.3 Million |
| Change in working capital | 12.41 Million | 2.78 Million | -1.4 Million | -4.54 Million | 6.86 Million | -321 Thousand |
| Other non-cash items | -10.4 Million | 4.02 Million | 10.11 Million | 689 Thousand | 24.63 Million | 92 Thousand |
| Investing Cash Flow | - | - | - | 6.36 Million | 5.92 Million | -3000.00 |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | 6.36 Million | 5.92 Million | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | -3000.00 |
| Financing Cash Flow | 11.37 Million | -1.59 Million | 112.06 Million | 26.31 Million | 29.52 Million | 5.37 Million |
| Debt repayment | -7.64 Million | -1.88 Million | -13.55 Million | -147 Thousand | - | -1.36 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -1.19 Million | 1.19 Million | - | - | 3 Million | - |
| Common Stock Issuance | 19.01 Million | 291 Thousand | 118.16 Million | 26.12 Million | 25 Million | 4.79 Million |
| Other Financing Activities | 1.19 Million | -273 Thousand | 7.45 Million | 339 Thousand | 1.51 Million | 585 Thousand |
| Accounts receivables | -763 Thousand | - | - | - | - | - |
| Accounts payables | 12.77 Million | 1.93 Million | -194 Thousand | 1.09 Million | -1.42 Million | 177 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 405 Thousand | 850 Thousand | -1.21 Million | -5.63 Million | 8.28 Million | -498 Thousand |
| Cash at beginning of period | 15.53 Million | 78.73 Million | 15.66 Million | 10.26 Million | 42 Thousand | 6.33 Million |
| Cash at end of period | 2.99 Million | 15.53 Million | 78.73 Million | 15.66 Million | 10.26 Million | 3.57 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | -6.36 Million | -5.92 Million | - |
| Net cash flow / Change in cash | -12.53 Million | -63.2 Million | 63.07 Million | 5.4 Million | 10.21 Million | -2.75 Million |
| Free Cash Flow | -23.91 Million | -61.6 Million | -48.99 Million | -20.91 Million | -19.3 Million | -8.12 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 1.71 Million | -2.66 Million | -5.45 Million | -37.88 Million | 10.49 Million | -29.49 Million |
| Depreciation & Amortization | 15 Thousand | 15 Thousand | 15 Thousand | 57 Thousand | 14 Thousand | 14 Thousand |
| Deferred income taxes | - | - | 5.54 Million | 7.91 Million | -23.9 Million | 18 Million |
| Stock-based compensation | 872 Thousand | 955 Thousand | 964 Thousand | 3.98 Million | 974 Thousand | 988 Thousand |
| Change in working capital | 1.3 Million | 456 Thousand | 5.12 Million | 12.41 Million | 5.87 Million | 3.97 Million |
| Other non-cash items | -4.87 Million | -3.4 Million | -8.11 Million | -10.4 Million | 799 Thousand | 616 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 742 Thousand | 2.17 Million | 2.32 Million | 11.37 Million | 2.49 Million | -2.31 Million |
| Debt repayment | -185 Thousand | -1.31 Million | -2.15 Million | -7.64 Million | -1.88 Million | -2.31 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -1.19 Million | - | - |
| Common Stock Issuance | 927 Thousand | 3.48 Million | 4.47 Million | 19.01 Million | 4.34 Million | - |
| Other Financing Activities | 927 Thousand | 4000.00 | 4.47 Million | 1.19 Million | 36 Thousand | -2.31 Million |
| Accounts receivables | 780 Thousand | -205 Thousand | -542 Thousand | -763 Thousand | 210 Thousand | 362 Thousand |
| Accounts payables | 418 Thousand | -1.13 Million | 7.08 Million | 12.77 Million | 2.88 Million | 474 Thousand |
| Inventory | - | - | - | - | -210 Thousand | -362 Thousand |
| Other working capital | 105 Thousand | 1.79 Million | -1.41 Million | 405 Thousand | 2.99 Million | 3.49 Million |
| Cash at beginning of period | 524 Thousand | 2.99 Million | 2.58 Million | 15.53 Million | 5.84 Million | 14.05 Million |
| Cash at end of period | 294 Thousand | 524 Thousand | 2.99 Million | 2.99 Million | 2.58 Million | 5.84 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -230 Thousand | -2.47 Million | 412 Thousand | -12.53 Million | -3.25 Million | -8.21 Million |
| Free Cash Flow | -972 Thousand | -4.64 Million | -1.91 Million | -23.91 Million | -5.74 Million | -5.9 Million |
GDI
XAR
3229
UBCP
SAKUMA
CAR